Information Provided By:
Fly News Breaks for July 20, 2016
JNJ
Jul 20, 2016 | 07:05 EDT
UBS raised its price target on Johnson & Johnson to $137 from $126 following the company's earnings report, citing raised guidance by the company, higher medical device volume trends, and strong pharmaceutical sales. UBS reiterated its Buy rating on Johnson & Johnson shares.